Mavacamten for HOCM

 

Mavacamten: Mechanism of Action, Indications, Dosing, Monitoring, and Clinical Evidence in Obstructive Hypertrophic Cardiomyopathy (HCM)

Introduction

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy, affecting approximately 1 in 500 individuals. In many patients, excessive myocardial contractility causes dynamic left ventricular outflow tract (LVOT) obstruction, leading to exertional dyspnea, chest pain, dizziness, syncope, and reduced exercise capacity.

For decades, treatment consisted mainly of beta-blockers, non-dihydropyridine calcium channel blockers, disopyramide, and septal reduction therapy. The introduction of Mavacamten represents a major breakthrough because it is the first disease-specific medication that directly targets the underlying pathophysiology of obstructive HCM rather than simply relieving symptoms.

Approved by the FDA in 2022 and recommended in contemporary ACC/AHA and ESC guidelines, Mavacamten has transformed the management of symptomatic obstructive HCM.

---

What is Mavacamten?

Mavacamten is a first-in-class selective cardiac myosin inhibitor.

Unlike conventional drugs that indirectly reduce heart contractility, Mavacamten directly decreases excessive actin-myosin cross-bridge formation, thereby reducing hypercontractility and improving myocardial relaxation.

It specifically addresses the molecular mechanism responsible for obstructive HCM.

---

Mechanism of Action

In obstructive HCM, mutations in sarcomeric proteins increase the number of myosin heads available to interact with actin, producing excessive force generation.

This leads to:

• Hypercontractility

• Dynamic LVOT obstruction

• Systolic anterior motion (SAM) of the mitral valve

• Elevated LV filling pressures

• Impaired diastolic relaxation

• Myocardial ischemia

• Progressive symptoms

Mavacamten works by:

• Selectively binding to cardiac myosin

• Stabilizing myosin in its energy-sparing "super-relaxed" state

• Reducing the number of actin-myosin cross-bridges

• Decreasing excessive contractility

• Improving ventricular relaxation

• Reducing LVOT gradient

• Improving cardiac efficiency

Importantly, it does not interfere with intracellular calcium handling, distinguishing it from traditional negative inotropes.

---

Physiological Effects

Treatment with Mavacamten results in:

• Reduced LVOT obstruction

• Decreased systolic anterior motion (SAM)

• Lower intracardiac filling pressures

• Improved diastolic function

• Reduced myocardial oxygen demand

• Increased stroke volume efficiency

• Better exercise tolerance

• Improvement in NYHA functional class

---

Indications

Current approved indication:

Adults with symptomatic obstructive hypertrophic cardiomyopathy (NYHA Class II–III).

Typical candidates include patients with:

• Resting or provoked LVOT gradient ≥50 mmHg

• Persistent symptoms despite optimal medical therapy

• Patients wishing to avoid septal reduction therapy

• Patients unsuitable for surgery or alcohol septal ablation

---

Who Should Not Receive Mavacamten?

Mavacamten should generally be avoided in patients with:

• LVEF below 55%

• Significant systolic dysfunction

• Pregnancy

• Breastfeeding

• Severe hepatic impairment

• Known hypersensitivity

Use caution in patients receiving potent CYP2C19 or CYP3A4 inhibitors or inducers because these drugs markedly alter plasma concentrations.

---

Dosing

Recommended starting dose:

5 mg orally once daily

Dose adjustments are based on:

• LVEF

• LVOT gradient

• Clinical symptoms

Available doses include:

2.5 mg

5 mg

10 mg

15 mg

Maximum dose:

15 mg once daily (depending on regional labeling)

Dose titration usually occurs every 4 weeks.

---

Echocardiographic Monitoring

Because excessive myocardial depression may occur, echocardiography is mandatory.

Baseline assessment should include:

• LVEF

• Resting LVOT gradient

• Provoked LVOT gradient

• Mitral regurgitation

• Presence of SAM

• Diastolic function

During dose titration:

Echo every 4 weeks

After stable dosing:

Echo approximately every 12 weeks

Therapy should be interrupted if:

LVEF falls below 50%

---

Clinical Monitoring

Patients should also be monitored for:

• Dyspnea

• Fatigue

• Syncope

• Heart failure symptoms

• NYHA class

• Blood pressure

• Drug interactions

---

Drug Interactions

Major interactions involve CYP2C19 and CYP3A4 pathways.

Avoid or use extreme caution with:

Strong CYP2C19 inhibitors

• Fluconazole

• Voriconazole

Strong CYP3A4 inhibitors

• Clarithromycin

• Ketoconazole

• Itraconazole

Strong enzyme inducers

• Rifampicin

• Carbamazepine

• Phenytoin

These drugs can significantly increase or decrease Mavacamten exposure, leading to toxicity or treatment failure.

---

Major Clinical Trials

EXPLORER-HCM

Phase III randomized trial

Key findings:

• Significant reduction in LVOT gradient

• Improved exercise capacity

• Better NYHA functional class

• Improved Kansas City Cardiomyopathy Questionnaire (KCCQ) score

• Reduction in need for septal reduction therapy

• Good overall safety profile

---

VALOR-HCM

Included patients already referred for septal reduction therapy.

Results demonstrated:

• Significant reduction in eligibility for surgery

• Marked symptom improvement

• Reduced LVOT gradients

• Better quality of life

Many patients no longer required invasive septal reduction therapy.

---

MAVA-LTE

Long-term extension study.

Demonstrated:

• Sustained reduction in LVOT gradient

• Durable symptomatic improvement

• Continued favorable safety profile

• Low incidence of systolic dysfunction with appropriate monitoring

---

Benefits of Mavacamten

Compared with conventional therapy, Mavacamten provides:

• Direct treatment of disease mechanism

• Reduction in LVOT obstruction

• Improvement in symptoms

• Better exercise capacity

• Improved quality of life

• Lower NT-proBNP levels

• Reduction in cardiac wall stress

• Potential avoidance of septal reduction procedures

---

Adverse Effects

Most common adverse events include:

• Dizziness

• Fatigue

• Reduced LVEF

• Heart failure due to excessive negative inotropy

• Syncope (rare)

The most important safety concern is excessive reduction in systolic function, highlighting the importance of regular echocardiographic surveillance.

---

Practical Clinical Pearls

• Confirm true obstructive HCM before prescribing.

• Optimize beta-blockers or calcium channel blockers first.

• Obtain baseline echocardiography.

• Assess LVOT gradient both at rest and with provocation.

• Monitor LVEF throughout therapy.

• Review all concomitant medications for CYP interactions.

• Interrupt therapy if LVEF falls below 50%.

• Reassess the need for septal reduction therapy after adequate medical treatment.

---

Guideline Recommendations

2024 AHA/ACC Guideline

Mavacamten is recommended for adults with symptomatic obstructive HCM who remain symptomatic despite guideline-directed medical therapy before proceeding to septal reduction therapy in appropriately selected patients.

2023 ESC Cardiomyopathy Guideline

Mavacamten is recommended as an effective option for symptomatic obstructive HCM with persistent LVOT obstruction despite optimal medical therapy, provided regular echocardiographic monitoring is available.

---

Future Directions

Several next-generation cardiac myosin inhibitors are under investigation, including aficamten, which may offer simpler dosing strategies and potentially reduced monitoring requirements. Ongoing studies continue to evaluate long-term effects on cardiac remodeling, fibrosis, and disease progression.

---

Key Takeaways

• Mavacamten is the first targeted cardiac myosin inhibitor for obstructive HCM.

• It directly reduces excessive sarcomere contractility rather than simply slowing the heart.

• It significantly decreases LVOT obstruction and improves symptoms.

• Careful echocardiographic monitoring is mandatory because of the risk of reduced LVEF.

• EXPLORER-HCM and VALOR-HCM established its efficacy and safety.

• Contemporary ACC/AHA and ESC guidelines recommend Mavacamten for appropriately selected patients with symptomatic obstructive HCM.

For more cardiology blogs, ECG learning resources, and guideline-based educational content, visit:

drmusmanjaved.com